AngioDynamics Inc
NASDAQ:ANGO

Watchlist Manager
AngioDynamics Inc Logo
AngioDynamics Inc
NASDAQ:ANGO
Watchlist
Price: 6.83 USD -1.73% Market Closed
Market Cap: 277.5m USD
Have any thoughts about
AngioDynamics Inc?
Write Note

Intrinsic Value

The intrinsic value of one ANGO stock under the Base Case scenario is 6.58 USD. Compared to the current market price of 6.83 USD, AngioDynamics Inc is Overvalued by 4%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ANGO Intrinsic Value
6.58 USD
Overvaluation 4%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
AngioDynamics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for ANGO cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about ANGO?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about AngioDynamics Inc

Provide an overview of the primary business activities
of AngioDynamics Inc.

What unique competitive advantages
does AngioDynamics Inc hold over its rivals?

What risks and challenges
does AngioDynamics Inc face in the near future?

Has there been any significant insider trading activity
in AngioDynamics Inc recently?

Summarize the latest earnings call
of AngioDynamics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for AngioDynamics Inc.

Provide P/S
for AngioDynamics Inc.

Provide P/E
for AngioDynamics Inc.

Provide P/OCF
for AngioDynamics Inc.

Provide P/FCFE
for AngioDynamics Inc.

Provide P/B
for AngioDynamics Inc.

Provide EV/S
for AngioDynamics Inc.

Provide EV/GP
for AngioDynamics Inc.

Provide EV/EBITDA
for AngioDynamics Inc.

Provide EV/EBIT
for AngioDynamics Inc.

Provide EV/OCF
for AngioDynamics Inc.

Provide EV/FCFF
for AngioDynamics Inc.

Provide EV/IC
for AngioDynamics Inc.

Show me price targets
for AngioDynamics Inc made by professional analysts.

What are the Revenue projections
for AngioDynamics Inc?

How accurate were the past Revenue estimates
for AngioDynamics Inc?

What are the Net Income projections
for AngioDynamics Inc?

How accurate were the past Net Income estimates
for AngioDynamics Inc?

What are the EPS projections
for AngioDynamics Inc?

How accurate were the past EPS estimates
for AngioDynamics Inc?

What are the EBIT projections
for AngioDynamics Inc?

How accurate were the past EBIT estimates
for AngioDynamics Inc?

Compare the revenue forecasts
for AngioDynamics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of AngioDynamics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of AngioDynamics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of AngioDynamics Inc compared to its peers.

Compare the P/E ratios
of AngioDynamics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing AngioDynamics Inc with its peers.

Analyze the financial leverage
of AngioDynamics Inc compared to its main competitors.

Show all profitability ratios
for AngioDynamics Inc.

Provide ROE
for AngioDynamics Inc.

Provide ROA
for AngioDynamics Inc.

Provide ROIC
for AngioDynamics Inc.

Provide ROCE
for AngioDynamics Inc.

Provide Gross Margin
for AngioDynamics Inc.

Provide Operating Margin
for AngioDynamics Inc.

Provide Net Margin
for AngioDynamics Inc.

Provide FCF Margin
for AngioDynamics Inc.

Show all solvency ratios
for AngioDynamics Inc.

Provide D/E Ratio
for AngioDynamics Inc.

Provide D/A Ratio
for AngioDynamics Inc.

Provide Interest Coverage Ratio
for AngioDynamics Inc.

Provide Altman Z-Score Ratio
for AngioDynamics Inc.

Provide Quick Ratio
for AngioDynamics Inc.

Provide Current Ratio
for AngioDynamics Inc.

Provide Cash Ratio
for AngioDynamics Inc.

What is the historical Revenue growth
over the last 5 years for AngioDynamics Inc?

What is the historical Net Income growth
over the last 5 years for AngioDynamics Inc?

What is the current Free Cash Flow
of AngioDynamics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for AngioDynamics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
AngioDynamics Inc

Current Assets 172.6m
Cash & Short-Term Investments 55m
Receivables 39.6m
Other Current Assets 78m
Non-Current Assets 121m
PP&E 39.7m
Intangibles 75.8m
Other Non-Current Assets 5.6m
Current Liabilities 76.7m
Accounts Payable 31.3m
Accrued Liabilities 30.2m
Other Current Liabilities 15.2m
Non-Current Liabilities 20.3m
Other Non-Current Liabilities 20.3m
Efficiency

Earnings Waterfall
AngioDynamics Inc

Revenue
292.7m USD
Cost of Revenue
-141.4m USD
Gross Profit
151.4m USD
Operating Expenses
-184.8m USD
Operating Income
-33.5m USD
Other Expenses
-209.6m USD
Net Income
-243m USD

Free Cash Flow Analysis
AngioDynamics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In the first quarter of fiscal 2025, AngioDynamics reported revenue of $67.5 million, up 1.1% year-over-year, primarily driven by strong growth in the Med Tech segment, particularly a 24.9% increase from the Auryon platform. Adjusted EBITDA loss narrowed to $200,000 from $1.1 million last year. The company is maintaining its revenue guidance of $282-$288 million for the year, projecting 10-12% Med Tech growth and 1-3% for Med Devices. Significant progress was noted in the rollout of AlphaVac, and a CE mark approval for Auryon opens new opportunities in Europe. The transition to outsourced manufacturing is expected to yield $15 million in cost savings by fiscal 2027.

What is Earnings Call?
Fundamental Scores

ANGO Profitability Score
Profitability Due Diligence

AngioDynamics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Revenue Growth Forecast
Negative 3-Years Revenue Growth
Declining ROIC
27/100
Profitability
Score

AngioDynamics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

ANGO Solvency Score
Solvency Due Diligence

AngioDynamics Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Low Altman Z-Score
57/100
Solvency
Score

AngioDynamics Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ANGO Price Targets Summary
AngioDynamics Inc

Wall Street analysts forecast ANGO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ANGO is 13.26 USD with a low forecast of 12.12 USD and a high forecast of 14.7 USD.

Lowest
Price Target
12.12 USD
77% Upside
Average
Price Target
13.26 USD
94% Upside
Highest
Price Target
14.7 USD
115% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ANGO?

Click here to dive deeper.

Dividends

AngioDynamics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for ANGO is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

ANGO Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

AngioDynamics Inc Logo
AngioDynamics Inc

Country

United States of America

Industry

Health Care

Market Cap

280.1m USD

Dividend Yield

0%

Description

AngioDynamics, Inc. is a medical device company, which engages in the development, manufacture, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. The company is headquartered in Latham, New York and currently employs 800 full-time employees. The company went IPO on 2004-05-27. Its devices are used in minimally invasive, image-guided procedures. Its product offerings include Endovascular Therapies, Oncology/Surgery (OS) and Vascular Access (VA). Its Endovascular Therapies product offerings support the medical areas of Thrombus Management, Atherectomy, Peripheral Products (Core) and Venous Insufficiency. Its OS product offerings includes a range of ablation technologies, including thermal tissue ablation systems, surgical resection and the Irreversible Electroporation (IRE) technology, the NanoKnife System. Its portfolio of VA products includes peripherally inserted central catheters (PICCs), midline catheters, implantable ports, dialysis catheters and related accessories and supplies.

Contact

NEW YORK
Latham
14 Plaza Dr
+15187981215.0
www.angiodynamics.com

IPO

2004-05-27

Employees

800

Officers

CEO, President & Director
Mr. James C. Clemmer
Executive VP & CFO
Mr. Stephen A. Trowbridge
Senior VP and GM of Global Vascular Access & Oncology Business Unit
Mr. Chad T. Campbell
Senior Vice President of Regulatory Affairs, Quality & Global Supply Chain
Mr. Warren G. Nighan
Senior VP & GM of Endovascular Therapies and International
Ms. Laura Piccinini
Vice President of Communications
Mr. Saleem M. Cheeks
Show More
Senior Vice President of Business Development & Strategy
Mr. Benjamin H. Davis
Senior Vice President of Human Resources
Ms. Marna I. Bronfen-Moore
Senior Vice President of Information Technology
Ms. Kim L. Seabury
Senior Vice President of Scientific & Clinical Affairs
Mr. Juan Carlos Serna
Show Less

See Also

Discover More
What is the Intrinsic Value of one ANGO stock?

The intrinsic value of one ANGO stock under the Base Case scenario is 6.58 USD.

Is ANGO stock undervalued or overvalued?

Compared to the current market price of 6.83 USD, AngioDynamics Inc is Overvalued by 4%.

Back to Top